About MyRxWallet
MyRxWallet North America Corporation, through its wholly-owned subsidiary MyRxWallet DAO, LLC, is revolutionizing healthcare data management with a decentralized, blockchain-based platform that empowers patients to securely manage and monetize their health data.
MyRxWallet is a global leader in healthcare delivery and advanced blockchain technologies. As part of its bold vision, MyRxWallet is developing the world’s first two hyperscale, multi-purpose-built mega data centers in India — seamlessly integrating AI, Web3, Blockchain, DAO, Staking, and enterprise-grade applications. These state-of-the-art facilities will power the next generation of healthcare and digital services for India’s 1.5 billion people and beyond on a global scale.
Our company specializes in Electronic Health Records (EHR) and Electronic Medical Records (EMR), built on a foundation of blockchain, artificial intelligence (AI), and Web3 technologies. MyRxWallet’s decentralized platform gives patients absolute ownership and control over their health data, secured by a tamper-proof blockchain infrastructure.
At the same time, MyRxWallet provides healthcare providers with hyperscale, enterprise-grade EHR solutions—ensuring they can deliver best-in-class diagnostics, personalized treatment plans, and continuous care. Our system is designed to eliminate overlooked or undiagnosed conditions while enabling seamless delivery of treatment directly to patients.
Beyond healthcare delivery and records management, MyRxWallet integrates AI-driven insights for personalized healthcare, pre-diagnosis support, and automated wellness planning. All of this is achieved while maintaining strict safeguards for privacy, consent, and data sovereignty.
By combining cutting-edge digital infrastructure with patient-centric healthcare innovation, MyRxWallet is building a future where healthcare is not only smarter and faster, but also fair, secure, and truly owned by patients themselves.
Key highlights about MyRxWallet:
• Mission & Approach: MyRxWallet focuses on patient-centric healthcare, ensuring data transparency and privacy. Their motto, “No Consent, No Access,” reflects a zero-trust, tamper-proof approach to health data.
• Technology: The platform leverages blockchain for secure data management, AI for personalized healthcare insights, and Web3 for decentralized control. This combination ensures robust security and innovative healthcare solutions.
• Healthcare Solutions: MyRxWallet offers comprehensive EHR and EMR solutions, enabling healthcare providers to deliver accurate diagnostics, personalized treatment plans, and continuous care. The platform aims to eliminate overlooked or undiagnosed conditions.
• Data Centers: MyRxWallet is developing two hyperscale mega data centers in India, designed to support AI, Web3, Blockchain, and enterprise-grade applications. These facilities will serve India’s 1.5 billion people and global markets.
• Patient Empowerment: The platform gives patients full ownership and control over their health data, allowing them to manage and monetize it securely.
• Future Vision: MyRxWallet envisions a future where healthcare is smarter, faster, and more equitable, with patients at the center of their healthcare journey.
• Company Structure: MyRxWallet North America Corporation and its subsidiary, MyRxWallet DAO, LLC, MyRxWallet Capital Partners, LLC, headquartered in Nevada united States. MyRxWallet Prana, Pvt. Ltd. Is located in India, a wholly owned subsidiary of MyRxWallet NAC.
In summary, MyRxWallet is at the forefront of integrating Hyperscale Technology for Web3, AI, Data Center, DAO, Staking, and Blockchain for healthcare to ensure that both patients and providers benefit from secure, efficient, and patient-driven health data management.
Our Leadership Team
MyRxWallet North America Corporation is led by a team of seasoned professionals with extensive experience in healthcare, technology, finance, and business development. Our leadership team is dedicated to driving innovation and excellence in healthcare delivery and data management.
Olivia Trinh | Chairman & CEO
Is currently a studying public health with a minor in finance at UNR. Upon completing her undergraduate, she intends to immediately pursue an MBA, all while forging MyRxWallet ahead as the leader in healthcare delivery.
Dr. Hanh Do, DO | Special Strategic Advisor to CEO
Dr. Do, formerly the CEO of MyRxWallet, she now serves as Special Strategic Advisor to the CEO. Dr. Do is currently a resident at UC Davis Hospital with a medical degree from Western University and a bachelor’s degree from UC Berkeley. She has extensive experience in clinical research and laboratory work, including serving as a Clinical Research Coordinator at Stanford University School of Medicine (2018–2020), where she managed projects, data collection, and regulatory compliance.
She also worked as a Laboratory Technician at AEMTEK, Inc., conducting food safety testing and quality control, and contributed to maternal healthcare studies and patient data analysis during her time at UCSF Medical Center.
Ms. Do brings a strong foundation in medical research, patient care, data analysis, and regulatory compliance, making her well-equipped to advance healthcare technology.
Binh Do | President & Chief Financial Officer
Binh Do, Chief Financial Officer at MyRxWallet, brings over five years of experience in finance and strategic management. As the Owner of BD Tax Group, he developed strategic business plans that drove profitability and established partnerships to diversify services.
As CFO of Swim 2000 Inc., he managed financial statements, tax filings, and compliance while spearheading budgeting, financial planning, and restructuring initiatives to improve operational efficiency and reduce costs. His expertise in financial strategy and operational optimization aligns MyRxWallet’s financial objectives with its mission to revolutionize healthcare through blockchain technology.
Mr. Do has not held directorships in publicly registered companies or investment companies under the Investment Company Act of 1940 in the past five years.
Dr. Venkatesh Pandi, MD & Ph.D. | Co-Chief Medical Officer & Co-CRO and Co-founder of Noah Therapeutics
Dr. Venkatesh Pandi brings to MyRxWallet over 23 years of leadership in the clinical research industry, combining deep medical expertise (M.B.B.S.) with a Ph.D. in Clinical Research to build, scale, and optimize high-quality research organizations.
Over the course of his career, Dr. Venkatesh has successfully led and executed more than 1,000 clinical studies, spanning bioavailability and bioequivalence programs, patient pharmacokinetic evaluations, and late-phase trials across a wide range of therapeutic areas and dosage forms.
His experience includes direct engagement with global regulatory authorities, having led teams through successful inspections and audits by the US FDA, EMA, WHO, ANVISA, UK MHRA, TGA, and NPRA. These interactions have consistently validated his operational rigor and established his organizations as trusted global partners for clinical sponsors.
As Co-Chief and strategic leader, Dr. Venkatesh’s vision is to build research environments that balance scientific credibility with operational agility. His leadership philosophy emphasizes compliance, transparency, and executional excellence, while upholding patient safety and ethical integrity as core principles.
By fostering a culture of innovation, accountability, and value creation, Dr. Venkatesh continues to position his organizations as globally competitive CRO partners of choice, delivering solutions that accelerate development timelines, reduce risk, and advance global health outcomes.
Upendra Chowdary | Co-COO & MSO
Mr. Chowdary brings with him over 18 years of experience in clinical research, Mr. Narra Upendra Chowdary has built a distinguished career defined by an unwavering commitment to quality, regulatory compliance, and ethical excellence in every facet of clinical trial operations. His professional journey spans Phase I through Phase III development as well as Bioavailability/Bioequivalence (BA/BE) studies, providing a comprehensive perspective on the full clinical research continuum.
Mr. Chowdary possesses extensive hands-on expertise in managing studies from protocol design to execution and regulatory submission, with proven familiarity in FDA, EMA, and other international regulatory frameworks. His strong adherence to ICH-GCP principles and global ethical standards has been instrumental in achieving consistent inspection readiness and scientific credibility across all programs.
As Joint Managing Director, he continues to champion operational excellence, cross-functional collaboration, and process integrity, fostering a culture of accountability and innovation. Guided by a deep understanding of both the scientific and ethical foundations of clinical development, Mr. Chowdary remains dedicated to advancing safe, effective, and accessible healthcare solutions, while reinforcing the organization’s position as a globally respected clinical research partner.
Dr. Vemulapalli Manaswini | MD & Principal Investigator
Dr. V. Manaswini earned her M.B.B.S. from Mediciti Institute of Medical Sciences (2017) and subsequently completed her M.D. in Pharmacology at MNR Medical College and Hospital (2020). Following her postgraduate training, she served as a Senior Resident at Gandhi Medical College and Hospital from August 2023 to August 2024, where she deepened her expertise in clinical pharmacology and patient-centered research practices.
In her current role as Principal Investigator at Noah Therapeutics, Dr. Manaswini leads and coordinates clinical research teams across various therapeutic studies, overseeing study design, data review, and regulatory compliance. Her work ensures that all research activities adhere to the highest ethical and scientific standards, while maintaining rigorous medical oversight throughout the clinical trial process.
With a strong foundation in pharmacological science and a passion for advancing evidence-based medicine, Dr. Manaswini is dedicated to supporting Noah Therapeutics’ mission of developing innovative, safe, and effective healthcare solutions for patients worldwide.
Dr. V. Raveendra Babu | Ph.D. & Pharm.D.
Dr. V. Raveenbabu Vemula brings over 22 years of core CRO experience in Bioavailability/Bioequivalence (BA/BE) study operations and Quality Assurance within leading Indian and global research organizations. He holds a B.Pharm., M.Pharm., and Ph.D. in Pharmaceutical Sciences from reputed Indian medical universities, combining deep scientific expertise with a proven track record of operational leadership.
Throughout his career, Dr. Raveenbabu has successfully led teams through numerous international regulatory inspections including those by the US FDA, EMA, UK MHRA, NPRA, GCC, ANVISA, ANSM, and DCGI—ensuring full compliance across both facility- and study-based audits. His ability to interpret complex regulatory and client requirements has been central to designing and operationalizing new BA/BE research centers, as well as establishing robust Quality Management Systems (QMS) for multiple CROs.
Research Solutions Pvt. Ltd., Hetero-Clians Labs Pvt. Ltd., ClinSync Clinical Research Pvt. Ltd., Quest Life Sciences Pvt. Ltd., GVK Biosciences (Aragen Life Sciences), and Aurobindo Pharma Ltd. He also serves as a CII-certified GCP & GLP trainer, delivering technical training and guest lectures to pharmacy and life-science institutions across India.
As Site Head – BA/BE Operations, Dr. Raveenbabu oversees all aspects of study design, quality compliance, and operational strategy, ensuring that Noah Therapeutics maintains the highest global standards of scientific integrity, regulatory excellence, and client trust.
Dr. C. Amulya Kiran Reddy | ER MD & Principal Investigator
Dr. Reddy is a qualified medical professional (M.B.B.S.) with over six years of clinical experience in emergency medicine and intensive care. Her career reflects a strong foundation in critical care management, acute patient stabilization, and multidisciplinary clinical coordination.
She began her medical career as a Duty Medical Officer at Swaroopa Hospital (2020–2021), where she gained early exposure to emergency response and acute care procedures. From 2022 to 2023, she served as an Emergency Physician and Intensivist at Indo-US Hospital, providing critical care support and leading interventions for high-acuity patients. She subsequently joined Nikhil Hospital (2023–2024) as an Intensivist/Critical Care Physician, further refining her expertise in patient management and intensive care protocols.
Parallel to her critical care responsibilities, Dr. Amulya contributed to QPS Bioserve India Pvt. Ltd. as an On-Call Screening Physician, overseeing volunteer assessments and study eligibility processes for clinical research programs.
Since January 2025, Dr. Amulya has been associated with Noah Therapeutics Pvt. Ltd. as a Principal Investigator in the Clinical Research Department. In this capacity, she manages study conduct, ensures regulatory compliance, provides medical oversight, and upholds the highest standards of patient safety and ethical integrity in all ongoing trials.
Dr. Anuradha Cingeetham — Ph.D. Human Genetics
Dr. Cingeetham is an accomplished life sciences professional with over 14 years of combined experience spanning academia, molecular research, and regulatory medical writing. Her career reflects a rare integration of academic instruction, scientific investigation, and clinical documentation expertise, making her a valuable asset to the life sciences and clinical research community.
Dr. Anuradha began her professional journey in academia, teaching and mentoring postgraduate students in life sciences. This experience not only strengthened her scientific foundation but also honed her ability to communicate complex biological concepts with clarity and precision—a skill that continues to define her excellence in medical writing.
Transitioning into research, she earned a Ph.D. in Human Genetics and completed a prestigious D.S. Kothari Postdoctoral Fellowship, focusing on molecular biology, cancer genomics, and human genetics. Over the following decade, she made notable contributions to leukemia and cancer research, gaining expertise in PCR, gene expression profiling, SNP analysis, DNA sequencing, and biomarker discovery. Her work has resulted in 23 peer-reviewed publications and presentations at both national and international scientific conferences.
In her current role as Senior Medical Writer at Noah Therapeutics Pvt. Ltd., Dr. Anuradha plays a critical role in the preparation of clinical study reports (CSRs), investigator brochures (IBs), protocols, and informed consent forms (ICFs) for both early- and late-phase clinical trials and BA/BE studies. She collaborates closely with clinical, regulatory, and scientific teams to ensure that every document meets ICH-GCP standards, sponsor expectations, and regulatory compliance requirements.
With a proven ability to synthesize complex scientific data into clear, accurate, and regulatory-compliant clinical documentation, Dr. Anuradha continues to bridge the gap between scientific discovery and clinical development, reinforcing Noah Therapeutics’ mission of advancing global healthcare through innovation and precision.
Mokros, Patrick | Chief Strategic Officer
Patrick Mokros, brings over two decades of expertise in financial services and business leadership.
Patrick Mokros, As the President of Empire Stock Transfer since 2006, Patrick has overseen operations for one of the most respected transfer agents in the small-cap space, providing services such as DTCC eligibility, dividend distribution, and proxy solicitation.
His leadership has been instrumental in helping numerous companies navigate the complex financial landscape, delivering exceptional results for clients and shareholders alike. In addition to his role at Empire Stock Transfer, Patrick has co-founded multiple ventures, including exospec and Wishlu, demonstrating his entrepreneurial acumen and ability to scale businesses across industries.
Mr. Mokros has not held directorships in publicly registered companies or investment companies under the Investment Company Act of 1940 in the past five years.
Okamura, Yu | Senior Developer
With years of hands-on experience in software development, Yu specializes in building robust, user-focused applications and systems, contributing to the technological foundation of MyRxWallet's decentralized healthcare platform.
Hume, David | Executive Assistant
With a comprehensive background in psychology and business development, David Hume brings invaluable expertise to MyRxWallet North America Corporation.